HNGE:NYSEHinge Health, Inc. Analysis

Hinge Health (HNGE) is trading at $84.05, comfortably above its 20‑day, 50‑day and 200‑day SMAs (70.7, 59.6 and 48.8), and the MACD line sits bullishly above its signal (6.99 vs 5.73). However, the RSI has surged to 84, flagging an overbought condition just shy of the 86.66 resistance level. Volume is on an upward trend, reinforcing the current bullish bias, while the 30‑day volatility of ~46% and a beta of 1.25 signal pronounced price swings.
On the fundamentals side, revenue jumped 47% YoY to $646 M with an impressive 81% gross margin and a 17.6% operating margin, and the company generated $447 M of free cash flow. Despite a trailing loss (‑78.9% profit margin) and a negative EPS of –$8.92, forward EPS is projected at $3.39, and the DCF fair‑value estimate of $212 suggests the stock is substantially undervalued relative to its intrinsic potential. Recent Investor Day guidance lifted 2026 revenue expectations to $818‑$824 M (≈40% growth) and analysts have upgraded to a “Buy” with a median target of $79, underscoring growing confidence in the company’s AI‑driven MSK platform.